MetaCap

MeiraGTx Holdings plc (MGTX)

NASDAQ: MGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.98-0.16 (-1.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MGTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$779.89M
52-week range
6.62 – 15.35
Day range
7.81 – 8.23
Volume / Avg
1.01M / 837.25K
Beta
—

52-week range

$6.62$15.35

MGTX stock today

Shares of MeiraGTx (MGTX) finished lower on Nov 20 at $7.98, a drop of 1.97% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, MGTX sits near the bottom of its 52-week range of $6.62 to $15.35: 48.0% below the high, set on Jul 7, 2026 and 20.5% above the low. MGTX is up 0.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 7.0%.

MeiraGTx trades at 9.2x its trailing twelve-month earnings per share of $0.87.

Summary generated from market data by MetaCap's automated system. Methodology

About MeiraGTx

Company profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Alexandria Forbes Ph.D.
Headquarters
New York, NY
Employees
386
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, MeiraGTx generated $81.4 million in revenue, up 144.6% from fiscal 2024, its 2nd consecutive year of revenue growth. MeiraGTx reported a net loss of $114.2 million, compared with a loss of $147.8 million a year earlier. Operating margin was -130.2%.

MeiraGTx annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2021FY 2021
Revenue$81.39M$33.28M$14.02M$15.92M$37.70M
Growth+144.57%+137.42%-11.95%-57.77%+142.25%
Net income$-114.20M$-147.79M$-84.03M$-129.62M$-79.56M
EPS (diluted)$-1.42$-2.12$-1.49$-2.87$-1.80

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$27.75+247.74%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.53 vs $-0.46
Surprise
-15.22%

MGTX news

All MGTX news

MeiraGTx peers

Health Care sector
MGTX peer companies
CompanyPrice% ChgMarket capCompare
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs MGTX
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs MGTX
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs MGTX
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs MGTX
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs MGTX
IMTXImmatics N.V.5.77-3.03%$878.58Mvs MGTX
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs MGTX
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs MGTX

Indexes, lists and sector

MeiraGTx stock FAQ

What is MeiraGTx's stock price today?

MGTX last traded at $7.98 as of Nov 20, 4:00 PM EST, down 1.97% on the day. Prices are delayed at least 15 minutes.

What is MGTX's P/E ratio?

MGTX trades at a trailing P/E ratio of 9.17.

Who is MeiraGTx's CEO?

Dr. Alexandria Forbes Ph.D. is the chief executive officer of MeiraGTx Holdings plc, which has about 386 employees.

What is the MGTX 52-week high?

The 52-week high for MGTX is $15.35 and the 52-week low is $6.62. The stock is currently 48.0% below its high.

Compare MGTX